19 results about "Specific immunotherapy" patented technology

Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

The present disclosure is based in part on studies on novel tolerogenic peptides derived from a protein expressed by a pancreatic cell, which have been developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed is a tolerogenic peptide capable of binding an MHC class II molecule independent of antigen processing for use in the treatment of type 1 diabetes, wherein the peptide is derived from a protein expressed by a pancreatic cell.

Methods and compounds for conferring kidney-glomerular-specific immunotherapy.

Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.

The present disclosure is based in part on research related to novel tolerogenic peptides derived from proteins expressed by pancreatic cells, developed for use in antigen-specific immunotherapy for type 1 diabetes. Disclosed are tolerogenic peptides that can bind to MHC class II molecules without relying on antigen processing, and are derived from proteins expressed by pancreatic cells, for use in the treatment of type 1 diabetes.

Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.

Disclosed is compositions and pharmaceutically acceptable formulations comprising the four peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6, as well as a kit comprising the compositions or pharmaceutically acceptable formulations, and methods of their preparation and their use in mitigation of peanut allergy and their uses in peanut allergen-specific immunotherapy.

Novel anti-effector moiety antibodies or antigen binding domains thereof and CARs that contain such effector moiety antigen binding domains, either with or without one or more booster elements, and host cells expressing the receptors, and nucleic acid molecules encoding the receptors are provided herein, as well as methods of use of same in a patient-specific immunotherapy that can be used to treat solid tumor cancers and other diseases and conditions.

Methods and compositions for use of tumor self-antigens in adoptive immunotherapy are disclosed herein, including search engines and algorithms for identifying tumor-specific immunotherapy targets. An example computer-implemented method can include receiving, by at least one processor, sequence data; identifying, by the at least one processor, one or more tumor-specific events associated with a plurality of molecular event classes from the sequence data; determining, by the at least one processor, a search space based on the one or more tumor-specific events; interrogating, by the at least one processor, a plurality of datasets based on the determined search space; and determining, by the at least one processor, one or more immunotherapy targets based on genetic aberrations from the sequence data.

The invention discloses a biomarker and a kit for diagnosing sepsis. In the application, it is found for the first time that the specificity of sepsis has unique CD38high mononuclear cell characteristics, and the CD38high mononuclear cell can be used as a target spot for specific immunotherapy of sepsis, especially bacterial sepsis, and is of great significance to improvement of diagnosis and clinical management; according to the application, the action mechanism of the monocyte CD38 is researched by taking the monocyte CD38 as a center, and it is found that blocking of the CD38 in the CD14 + monocyte can regulate glycolysis switch, reduce generation and oxidative stress of type I interferon and improve disease symptoms of sepsis patients, so that a foundation is laid for subsequent screening and development of sepsis treatment drugs.

The present disclosure provides an improved method for identify proteins having a conformation that is specific to a cell type.

Novel therapeutic immunotherapy compositions comprising at least two vectors, each vector encoding a functional CAR, whereby the combination of vectors results in the expression of two or more non-identical binding domains, wherein each vector encoded binding domain(s) are covalently linked to a transmembrane domain and one or more non-identical intracellular signaling motifs are provided herein as well as are methods of use of same in a patient-specific immunotherapy that can be used to treat cancers and other diseases and conditions.

Provided are amino acid and nucleic acid sequences that can promote antigen-specific tolerance in a human subject in need thereof. In addition, delivery vehicles comprising such nucleic acids (e.g., mRNAs) are described. Also disclosed are methods of using these agents to control unwanted immune responses and treat disease in a human subject in need thereof.

The present application belongs to the technical field of biological medicine, and particularly relates to a tumor neoantigen polypeptide based on Q61K mutation of tumor driver gene NRAS and application thereof. The present application aims to solve the technical problem of the prior art, and provides a specific immunotherapy scheme for Q61K mutation of tumor driver gene NRAS based on MHC-II molecules. The technical scheme for solving the above technical problem is to provide a tumor neoantigen polypeptide based on Q61K mutation of NRAS gene. The amino acid sequence of the antigen peptide is GKEEYSAMRDQYMRT. The antigen peptide of the present application can significantly activate human specific T cells against NRAS mutation, so as to increase the killing ability of T cells to NRAS mutant tumor cells, and can be used for preparing a drug for preventing and treating NRAS mutant tumor, and particularly for preparing a tumor cell vaccine.

Methods and compositions for use of tumor self-antigens in adoptive immunotherapy are disclosed herein, including search engines and algorithms for identifying tumor-specific immunotherapy targets. An example computer-implemented method can include receiving, by at least one processor, sequence data; identifying, by the at least one processor, one or more tumor-specific events associated with a plurality of molecular event classes from the sequence data; determining, by the at least one processor, a search space based on the one or more tumor-specific events; interrogating, by the at least one processor, a plurality of datasets based on the determined search space; and determining, by the at least one processor, one or more immunotherapy targets based on genetic aberrations from the sequence data.

The invention discloses an endoplasmic reticulum membrane coated PLGA-poly T / GPC3 mRNA vaccine and a preparation method thereof, and the preparation method comprises the following steps: step 1, dissolving dioleoyl lecithin, 1, 2-dioleoyl-sn-glycerol-3-phosphate-L-serine, GPC3 mRNA and PLGA-poly T with an organic solvent, and then carrying out reduced pressure rotary evaporation to remove the organic solvent to obtain a lipid membrane; and 2, adding ultrapure water to hydrate the lipid membrane, then adding the endoplasmic reticulum membrane, carrying out ultrasonic treatment, centrifuging, and taking the supernatant, thereby obtaining the endoplasmic reticulum membrane coated PLGA-poly T / GPC3 mRNA vaccine P-(H)-m (at) EMLN. GPC3 mRNA specifically expressed in liver cancer tissue is selected, based on a unique ploy A tail structure of mRNA, a safe material PLGA approved by FDA is subjected to poly T modification, and safe entrapment of GPC3 mRNA is achieved through hydrogen-bond interaction generated by a zipper type structure of basic group interworking between A and T; meanwhile, the endoplasmic reticulum membrane is extracted for carrier coating so as to enhance the immunogenicity of the carrier and avoid the degradation of the endosome of the vaccine, so that the endoplasmic reticulum membrane coated bionic GPC3 mRNA nano vaccine (P-(H)-m (at) EMLN) is constructed for specific immunotherapy of liver cancer, is high in safety and has wide clinical transformation potential.

A method for coordinating the manufacturing of an expanded cell therapy product for a patient may include receiving a cell order request to expand the cell therapy product for the patient; generating a patient-specific identifier or cell order identifier associated with the cell order request; and initiating a process to expand the cell therapy product from at least some of a solid tumor obtained from the patient. If acceptance parameters for the expansion cell therapy product do not meet certain acceptance criteria at a second time point subsequent to a first time point in the expansion process, it is determined whether re-performing the expansion of the cell therapy product using the cell expansion technique is possible from the first time point based on the acceptance parameters at the second time point. If such re-performing the expansion is possible, patient treatment events that use the expanded cell therapy product are rescheduled.

This invention provides a method for enhancing the efficacy, safety, and / or tolerance of grass allergen-specific subcutaneous immunotherapy (SCIT) regimens in subjects with grass allergies. [Solution] A method is provided which includes administering a therapeutic composition containing an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or its antigen-binding fragment, to a subject in need.